Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Marion Wiesmann

Keith Bruce Pfister

Allan S Wagman

Simon C Ng

James Clifford Sutton

Martin Sendzik

Savithri Ramurthy

Sabina Pecchi

Paul Andrew Barsanti

Zhi-Jie Ni

Carla C Heise

Hong Yang

Daniel J Poon

Weibo Wang

Mark Knapp

Jiong Lan

Matthew T Burger

Aaron Matthew Smith

Mika Lindvall

Timothy D Machajewski

Wendy Fantl

Teresa E Pick

Yanchen Zhang

Elizabeth J Mieuli

Anu Sharma

Victoria Sung

Joelle Verhagen

Sarah Bartulis

Charles Voliva

Thomas Hendrickson

Liana M Klivansky

William Lenahan

Susan Kaufman

Kelly Frazier

Alicia Louie

Edwin Iwanowicz

Paul A Renhowe

Cynthia Shafer

Christopher McBride

Stephen David Harrison

David M Ryckman

Vivien W Chan

Eric Harwood

Elisa Jazan

William R McCrea

Shaopei Cai

Shuguang Zhu

Kelly Wayman

Gordana Babic Atallah

Johanna M Jansen

Xiao Shang

Dirksen Bussiere

Joyce Chou

Hanne Merritt

Timothy D Dawes

Xiaohua Xin

Gordana Ataliah

Glenn C Michelson

Xiahua Xin

Hanne Meritt

Joel B Silver

Aaron Smith

Mika K Lindvall

William P Lenahan

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. 

Pyrimidine derivatives used as PI-3 kinase inhibitors

A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application.

Methods for treating drug resistant cancer

Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

CSF-1R inhibitors, compositions, and methods of use

Pyrimidine derivatives used as PI-3-kinase inhibitors

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. 

Inhibition of FGFR3 and treatment of multiple myeloma

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. 

Benzimidazole quinolinones and uses thereof

Growing community of inventors

Brisbane, CA, United States of America

Marion Wiesmann